Novartis could settle for $1B as part of federal kickback lawsuit: report

Novartis
Novartis could be approaching a $1 billion settlement in a long-running kickback scheme lawsuit in federal court. (Novartis)

Six years after federal prosecutors first targeted Novartis for an alleged kickback scheme involving $10,000 dinners and fishing trips for doctors, signs pointed to the Swiss drugmaker finally having its day in court. Now, it looks like that may not happen.

Novartis could be approaching a billion-dollar settlement with the U.S. government as part of a whistleblower lawsuit accusing the company of bribing doctors to boost subscriptions of its drugs, sources told Stat. Novartis declined to comment Thursday on the possible settlement. 

In early April, U.S. District Judge Paul Gardephe cleared the way for the lawsuit to reach a jury trial after Novartis requested the suit be tossed based on a lack of evidence of a “nationwide kickback scheme” and a clear quid pro quo between the company and doctors allegedly on its payroll.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The most eye-popping claims in the lawsuit read like corporate corruption out of the world of fiction, with Novartis allegedly treating doctors to $10,000 dinners at Nobu, a chic New York seafood restaurant, and wild nights out at Hooters. In one instance, whistleblowers said the company held a sham promotional speaking event on a fishing boat.

RELATED: Did Novartis hand out kickbacks or host educational dinners? A jury may decide

Gardephe said those incidents were just a few of some 79,000 events admissible as trial evidence after federal prosecutors alleged a “companywide scheme” to boost scripts that defrauded the U.S. government of millions in Medicare and Medicaid billing over the span of nearly a decade.

Novartis spokesman Eric Althoff said in early April the promotional events were not opportunities to bribe doctors but instead part of the company’s educational program to inform physicians on the company’s drugs.

“Novartis strongly believes in the importance of peer-to-peer education,” he said. “Through these speaker programs, we provide information to healthcare professionals regarding the benefits and appropriate use of our medicines to help ensure that any prescription decisions are in the best interest of patients.”

RELATED: Novartis bribery investigation craters after Greek prosecutors clear 4 officials

A settlement in the Manhattan federal suit could wind down a second major investigation into Novartis’ business practices after four Greek government officials were cleared in April as part of a wide-ranging bribery probe alleging payments between the company and 10 politicians.

Corruption investigators returned a report to the Greek Parliament listing only former health minister Andreas Loverdos’ name as part of the probe, but Kathimerini reported investigators found no evidence Loverdos ever received a bribe.

However, other investigations into Novartis have gained more traction in recent years, including a $390 million civil settlement with the feds in 2015 on claims it worked with specialty pharmacies to push two of its drugs in exchange for paying rebates.

In addition, Novartis was flagged in former U.S. special counsel Robert Mueller's Russian collusion investigation in November 2017 after Michael Cohen, former personal attorney for President Donald Trump, acknowledged receiving $1.2 million from the company. NBC News reported a senior Novartis official said the payments followed Cohen pledging access to the Trump administration after his inauguration.

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.